- •Preface
- •Contents
- •Contributors
- •1: Living with Diabetic Retinopathy: The Patient’s View
- •My Patient Experience
- •Others’ Experiences
- •Photos of the Meaning of Diabetes
- •References
- •2: Diabetic Retinopathy Screening: Progress or Lack of Progress
- •Definitions of Screening for Diabetic Retinopathy
- •Studies Reporting the Prevalence of Diabetic Retinopathy
- •Reports on Blindness and Visual Impairment
- •Is There Evidence That Treatment for Sight-Threatening Diabetic Retinopathy Is Effective and Agreed Universally?
- •The Evidence That Diabetic Retinopathy Can Be Prevented or the Rate of Deterioration Reduced by Improved Control of Blood Glucose, Blood Pressure and Lipid Levels, and by Giving Up Smoking
- •The Evidence that Laser Treatment Is Effective
- •The Evidence That Vitrectomy for More Advanced Disease Is Effective
- •Progress of Lack of Progress in Screening for Diabetic Retinopathy in Different Parts of the World
- •References
- •3: Functional/Neural Mapping Discoveries in the Diabetic Retina: Advancing Clinical Care with the Multifocal ERG
- •Introduction
- •The Diabetes Epidemic
- •Current Treatment Focus
- •Vasculopathy and Neuropathy of the Retina
- •The Early Efforts
- •Some Breakthroughs
- •Predictive Models of Visible Retinopathy Onset at Specific Locations
- •How Is the mfERG Measured and What is it Measuring?
- •Where Are These Neural Signals Generated in the Retina?
- •Some Key Results
- •Adolescents and Adult Diabetes
- •Type 1 vs. Type 2: Differences in Retinal Function
- •References
- •4: Corneal Diabetic Neuropathy
- •Introduction
- •Corneal Confocal Microscopy
- •Corneal Nerves and Diabetes
- •Conclusion
- •References
- •5: Clinical Phenotypes of Diabetic Retinopathy
- •Natural History
- •MA Formation and Disappearance Rates
- •Alteration of the Blood–Retinal Barrier
- •Retinal Capillary Closure
- •Multimodal Macula Mapping
- •Clinical Retinopathy Phenotypes
- •Relevance for Clinical Trial Design
- •Relevance for Clinical Management
- •Targeted Treatments
- •References
- •6: Visual Psychophysics in Diabetic Retinopathy
- •Introduction
- •Visual Acuity
- •Color Vision
- •Contrast Sensitivity
- •Macular Recovery Function (Nyctometry)
- •Perimetry
- •Microperimetry (Fundus-Related Perimetry)
- •Conclusion
- •References
- •7: Mechanisms of Blood–Retinal Barrier Breakdown in Diabetic Retinopathy
- •The Protective Barriers of the Retina
- •The Inner and the Outer BRB
- •Inflammation and BRB Permeability
- •Leukocyte Mediators of Vascular Leakage
- •Other Mediators of Leukocyte Recruitment in DR
- •Structural Compromise of the BRB
- •Vascular Endothelial Growth Factor
- •Anti-VEGF Properties of Natriuretic Peptides
- •Proposed Model of BRB Breakdown in DR
- •Key Role of AZ in VEGF-Induced Leakage
- •Azurocidin Inhibition Prevents Diabetic Retinal Vascular Leakage
- •References
- •8: Molecular Regulation of Endothelial Cell Tight Junctions and the Blood-Retinal Barrier
- •The Blood-Retinal Barrier
- •The Retinal Vascular Barrier
- •The Junctional Complex
- •ZO Proteins
- •Claudins
- •Junctional Adhesion Molecules
- •Occludin and Tricellulin
- •Vascular Permeability in Diabetic Retinopathy
- •VEGF-Induced Regulation of Endothelial Permeability
- •Occludin Phosphorylation and Permeability
- •Protein Kinase C in Regulation of Barrier Properties
- •Conclusions
- •References
- •9: Capillary Degeneration in Diabetic Retinopathy
- •Vascular Nonperfusion in Diabetes: Mechanisms
- •Molecular Causes of Capillary Degeneration
- •Unexplained Aspects of Diabetes-Induced Degeneration of Retinal Capillaries
- •What Is the Relation Between the Retinal Vasculature and Neuronal Retina Structure and Function in Diabetes?
- •Conclusion
- •References
- •10: Proteases in Diabetic Retinopathy
- •Proteases in Retinal Vasculature
- •Extracellular Proteases
- •Urokinase Plasminogen Activator System (uPA/uPAR System)
- •Matrix Metalloproteinases
- •Endogenous Inhibitors of Proteases
- •Tissue Inhibitors of Metalloproteinases (TIMPs)
- •Plasminogen Activator Inhibitors (PAI)
- •Proteases in Retinal Neovascularization
- •Tissue Inhibitor of Matrix Metalloproteinases in Retinal Neovascularization
- •Inhibition of Retinal Angiogenesis by MMP Inhibitors
- •Inhibition of Retinal Angiogenesis by Inhibitors of the uPA/uPAR System
- •Proteases in Diabetic Macular Edema
- •Conclusion
- •References
- •11: Proteomics in the Vitreous of Diabetic Retinopathy Patients
- •Introduction
- •Vitreous Anatomy
- •A Candidate Approach
- •Proteomic Approaches
- •Vitreous Acquisition
- •Sample Pre-Fractionation
- •Mass Spectrometry
- •Spectral Analysis
- •Data Analysis
- •The Vitreous Proteome
- •2-DE-Based Proteomics
- •1-DE-Based Proteomics
- •Summary and Conclusions
- •References
- •12: Neurodegeneration in Diabetic Retinopathy
- •Introduction
- •Histological Evidence
- •Early Pathology Studies
- •Histological Evidence of Apoptosis
- •Gross Morphological Changes in the Retina
- •Reductions in Numbers of Surviving Amacrine Cells
- •Retinal Ganglion Cell Loss
- •Abnormalities in Ganglion Cell Morphology
- •Centrifugal Axon Abnormalities
- •Nerve Fiber Layer Thickness
- •Biochemical Evidence of Neurodegeneration and Cell Death
- •Functional Evidence of Neurodegenerative Changes
- •Electrophysiological Evidence for Neurodegeneration
- •Optic Nerve Retrograde Transport
- •Other Changes in Visual Function
- •Summary and Conclusions
- •References
- •13: Glucose-Induced Cellular Signaling in Diabetic Retinopathy
- •Introduction
- •Cellular Targets in DR
- •Endothelial Cell (EC) Dysfunction
- •Endothelial-Pericyte Interactions
- •Endothelial-Matrix Interactions
- •Signaling Mechanisms in DR
- •Altered Vasoactive Factors
- •Alteration of Metabolic Pathways
- •Polyol Pathway
- •Hexosamine Pathway
- •Protein Kinase C Pathway
- •Activation of Other Protein Kinases
- •Mitogen-Activated Protein Kinase (MAPK)
- •Increased Oxidative Stress
- •Protein Glycation
- •Aberrant Expression of Growth Factors
- •Transcription Factors
- •Transcription Regulators
- •Concluding Remarks
- •References
- •Introduction
- •The Growth-Hormone/Insulin-Like Growth Factor Pathway in Proliferative Retinopathies
- •Proliferative Diabetic Retinopathy (PDR)
- •Retinopathy of Prematurity (ROP)
- •Animal Models of Proliferative Retinopathies
- •IGFBP-3 as a Regulator of the Growth-Hormone/ Insulin-Like Growth Factor Pathway
- •Conclusion
- •References
- •15: Neurotrophic Factors in Diabetic Retinopathy
- •Diabetic Retinopathy
- •Neurotrophic Factors
- •Neurotrophins and Others
- •Nerve Growth Factor
- •Glial-Cell-Derived Neurotrophic Factor
- •Ciliary Neurotrophic Factor
- •Anti-angiogenic Neurotrophic Factors
- •Pigment-Epithelium-Derived Factor
- •SERPINA3K
- •Brain-Derived Neurotrophic Factor
- •Fibroblast Growth Factors
- •Insulin and Insulin-Like Growth Factor 1
- •Erythropoietin
- •Vascular Endothelial Growth Factor
- •Neurotrophic Factors and the Future of DR Research
- •References
- •16: The Role of CTGF in Diabetic Retinopathy
- •Introduction
- •ECM Remodeling and Wound Healing Mechanisms in Diabetic Retinopathy
- •ECM Remodeling in PCDR
- •Wound Healing Mechanisms in PDR
- •CTGF Structure and Function
- •CTGF in the Eye
- •CTGF in Ocular Fibrosis
- •CTGF in Ocular Angiogenesis
- •CTGF in Diabetic Retinopathy
- •CTGF in BL Thickening in PCDR
- •AGEs and CTGF in BL Thickening in PCDR
- •Role of VEGF in BL Thickening
- •BL Thickening in Diabetic CTGF-Knockout Mice
- •CTGF in PDR
- •Role of CTGF and VEGF in the “Angiofibrotic Switch” in PDR
- •Conclusions
- •References
- •17: Ranibizumab and Other VEGF Antagonists for Diabetic Macular Edema
- •Introduction
- •Pathogenesis of DME and Current Standard of Care
- •Ranibizumab for DME
- •Pegaptanib for DME
- •Bevacizumab for DME
- •VEGF Trap-Eye for DME
- •Other Considerations in the Management of DME
- •Combination Treatment for DME
- •DME and Quality of Life
- •Conclusions
- •References
- •18: Neurodegeneration, Neuropeptides, and Diabetic Retinopathy
- •Introduction
- •Neuropeptides Involved in the Pathogenesis of DR
- •Glutamate
- •Angiotensin II
- •Pigment Epithelial-Derived Factor
- •Somatostatin
- •Erythropoietin
- •Docosahexaenoic Acid and Neuroprotectin D1
- •Brain-Derived Neurotrophic Factor
- •Glial Cell Line-Derived Neurotrophic Factor
- •Ciliary Neurotrophic Factor
- •Adrenomedullin
- •Concluding Remarks and Therapeutic Implications
- •References
- •19: Glial Cell–Derived Cytokines and Vascular Integrity in Diabetic Retinopathy
- •Introduction
- •The BRB Functional Unit Composed of Glial and Endothelial Cells
- •Tight Junctions Between Endothelial Cells Are Substantial Barrier of the BRB
- •Major Cytokines Derived from Glial Cells Affecting Tight Junctions of the BRB
- •VEGF
- •GDNF
- •APKAP12
- •A Possible Treatment of the Retinopathy with Retinoic Acid Analogues
- •Conclusion
- •References
- •20: Impact of Islet Cell Transplantation on Diabetic Retinopathy in Type 1 Diabetes
- •Introduction
- •What Are the Benefits and Risks of Reducing Blood Glucose?
- •On Average, 3 Years Was Required to Demonstrate the Beneficial Effect of Intensive Treatment
- •The Earlier in the Course of Diabetes That Intensive Therapy Is Initiated, Even Before the Onset of Retinopathy, the Greater the Long-Term Benefits
- •Risk Reduction in the Primary Prevention Cohort
- •Risk Reduction in the Secondary Prevention Cohort
- •There Was No Glycemic Threshold Regarding Progression of Retinopathy
- •Diabetic Ketoacidosis (DKA)
- •Efforts to Normalize Blood Glucose Are Associated with Weight Gain in People with Type 1 Diabetes
- •Connecting Peptide (C-Peptide) Responders Have Less Risk of Progression of Retinopathy
- •Effects of Improved Control on Retinopathy Were Sustained in the Long-Term
- •Quality of Life Measure
- •“Metabolic Memory”: A Phenomenon Producing a Long-Term Beneficial Influence of Early Metabolic Control on Clinical Outcomes
- •Need for a More Physiologic Glycemic Control Regimen
- •Effect of Intensive Insulin Therapy on Hypoglycemia Counterregulation
- •b Cell Function
- •Whole Pancreas Transplantation
- •Effect of SPK Transplantation on Diabetic Retinopathy
- •Islet Cell Transplantation
- •Adverse Effects of Chronic Immunosuppression
- •Effect of Islet Cell Transplantation on Retinopathy
- •References
- •Index
4
Corneal Diabetic Neuropathy
Edoardo Midena
CONTENTS
INTRODUCTION
CORNEAL CONFOCAL MICROSCOPY
CORNEAL NERVES AND DIABETES
CONCLUSION
REFERENCES
Keywords Sub-basal corneal nerve plexus • Corneal nerve fibers • Corneal confocal microscopy
• Peripheral diabetic neuropathy
INTRODUCTION
The prevalence of diabetes mellitus is dramatically increasing worldwide, and consequently, the prevalence of chronic complications due to diabetes will increase in the near future [1]. The most common cause of chronic disability in diabetic patients is diabetic neuropathy, mainly, peripheral diabetic neuropathy. Peripheral diabetic neuropathy affects 50% of diabetic patients within 25 years of diagnosis [2]. Long-term effects of undetected and untreated peripheral diabetic neuropathy can lead to foot infections that do not heal, as well as foot ulcers. Patients may require subsequent amputation of the foot and digits, which can lead to a decreased quality of life and increased mortality [3].
The effective and reliable diagnosis and quantification of peripheral diabetic neuropathy are relevant in defining at risk patients, decreasing patient morbidity, and assessing new therapies [4, 5]. The clinical diagnosis of peripheral diabetic neuropathy is often missed or peripheral neuropathy is lately diagnosed, mainly because a simple noninvasive method for early detection of peripheral diabetic neuropathy is not yet available [6]. Clinical diagnosis is commonly made only when patients with peripheral diabetic neuropathy become symptomatic. Early diagnosis is currently based on electrophysiological tests or on skin biopsy, probably the gold standard in identifying small fiber peripheral diabetic neuropathy. Electrophysiological tests cannot detect the minute fiber nerve fiber damage in patients with diabetes [7]. Although skin biopsy may detect the minute damage in small peripheral nerve fibers, it has a major limitation because skin biopsy is an invasive test [8, 9].
From: Ophthalmology Research: Visual Dysfunction in Diabetes
Edited by: J. Tombran-Tink et al. (eds.), DOI 10.1007/978-1-60761-150-9_4 © Springer Science+Business Media, LLC 2012
45
46 |
Midena |
Recently, a new approach to the detection of very early small fiber peripheral diabetic neuropathy has been proposed and validated. It involves the detection and quantification of the alteration of corneal nerves in diabetes, mainly the subbasal corneal nerve plexus [10]. This is a monolayer of nerve fibers located at the border between corneal epithelium and stroma, which may be detected in vivo even in a noninvasive way (see below) and probably represents the best model to have clinical information on diabetic peripheral neuropathy.
CORNEAL CONFOCAL MICROSCOPY
Corneal confocal microscopy (CCM) is a diagnostic test used to investigate at a microscopic level the different layers of the cornea. It is based on the same physical principle of any confocal microscope, allowing to have in focus just one layer of the examined tissue. Light reflected by any layer out of focus is eliminated allowing to have a high magnification, sharp image of the layer under investigation. Using corneal confocal microscope, the individual structures of any corneal layer may be easily documented: from the endothelium through the stroma (containing keratocytes, nerve fibers, and sometimes Langherans cells) up to the epithelium (with each layer) and tear film. The procedure may be a contact or noncontact one. The noncontact procedure allows to repeat CCM in a safe way, as much as necessary and with high reliability [10]. In our studies, CCM was performed by using Confoscan 4.0 (Nidek, Gamogori, Japan) equipped with an Achroplan nonapplanating ×40 immersion objective lens (Zeiss, Oberkochen, Germany) and with a Z-ring adapter system. Each examination is performed according to a standard procedure, as previously described [11]. Briefly, before the examination, a drop of topical anesthetic (0.4% oxybuprocaine chlorohydrate) is instilled in the lower conjunctival fornix of the eye. One drop of 0.2% polyacrylic gel is applied onto the objective tip to serve as an immersion fluid. The patient is positioned in the chin and forehead rest, and when an image of stroma appears on the monitor of the confocal microscope, the recording button is pressed and a micrometric motor-driven system automatically completes the alignment. The focal plane is automatically moved to reach the anterior chamber and begins recording several scans of the entire depth of the cornea. The Z-ring device is used for all examinations, and only the central cornea is analyzed. Illumination intensity is kept constant in all cases. The images collected using this procedure are analyzed in a qualitative and/or quantitative way. The endothelium is automatically analyzed using a dedicated software available with the machine. Both stromal and epithelial cells may be quantified in a semiautomatic way. The analysis of corneal sub-basal nerve plexus (CSNP) has been recently validated in a large group of normal and pathological eyes (Figs. 1 and 2) [10].
The assessment of CSNP was performed according to the following standardized procedure. The standard dimension of each image produced was 340 × 255 mm (area = 0.132 mm2) with an optical section thickness of 5.5 mm. For each examined cornea, the best sharp focus frame of CSNP was chosen. For each frame of the CSNP images, five parameters were analyzed: nerve fiber length (NFL), number of fibers (NF), number of branching (NBr), number of beadings (NBe), and fiber tortuosity (FT) (Fig. 3). NFL was calculated using an image processing computer tool, the Neuron J© program to
Corneal Diabetic Neuropathy |
47 |
Fig. 1. Corneal subbasal nerve plexus (CSNP) in a normal subject, as shown by corneal confocal microscopy (CCM). It appears as a monolayer of straight nerve fibers with hyperreflective spots along the nerve (nerve beadings).
Fig. 2. CSNP in diabetes, examined with CCM. The most evident aspect is the reduction of nerve beadings (colored in red) along the nerve fibers.
outline nerve fibers from each CSNP frame. NFL for each image was calculated as the total length of the nerves (micrometers) divided by the area of the image (0.132 mm2) and expressed as micrometers per square millimeters (mm/mm2). NF was manually calculated and defined as the total number of principal nerve trunks and their branches per image. NBr was manually calculated and defined as the total NBr per image. NBe was defined as the number of hyperreflective points manually calculated considering 100 mm
48 |
Midena |
Fig. 3. Normal nerve tortuosity in the corneal subbasal nerve layer.
of one fiber. The fiber was randomly chosen by the operator between all the best focused fibers. The same standard magnification was kept for all the images during the counting. The score system proposed by Oliveira-Soto and Efron [12] was used to analyze FT.
CORNEAL NERVES AND DIABETES
The cornea is the most densely innervated tissue in the body and is richly supplied by sensory and autonomic nerve fibers [13, 14]. Nerve bundles enter the cornea at the periphery in a radial manner parallel to the corneal surface. The nerve bundles lose their perineurium and myelin sheaths approximately 1 mm from the limbus and continue into the cornea surrounded by Schwann cell sheaths, and then subdivide several times into smaller branches. Stromal nerve trunks move from the periphery toward the corneal center and eventually turn 90°, proceeding toward the corneal surface and penetrating Bowman’s layer. After penetrating Bowman’s layer, the large nerve bundles divide into several smaller bundles, which turn another 90° and continue parallel to the corneal surface between Bowman’s layer and the basal epithelial cell layer, creating the subbasal corneal nerve plexus. The CSNP is characterized by local axon enlargements, or beading, which are accumulations of mitochondria and glycogen particles located at the periphery of the bundle. Corneal nerve fibers exert important trophic influences on the corneal epithelium and contribute to the maintenance of a healthy ocular surface [13]. Corneal abnormalities caused by diabetes include superficial punctuate keratopathy, recurrent epithelial defects, neurotrophic keratopathy, and corneal ulcer [15–19]. These abnormalities have been reported to occur in 50–74% of patients with diabetes who never underwent surgery, and many of these patients are asymptomatic [18, 19]. Corneal sensation is reduced in diabetic patients and progresses with the severity of neuropathy, suggesting that corneal nerve fiber damage accompanies diabetic somatic nerve fiber damage [20–22], one of the most important and invalidating diabetic chronic complica-
Corneal Diabetic Neuropathy |
49 |
Fig. 4. Altered (increased) tortuosity of the subbasal nerve plexus in diabetes. This image is classified as stage 4 tortuosity.
tions [23]. A growing interest in corneal morphology in diabetic patients, especially in CSNP, is documented [21, 24–27]. Corneal nerve changes secondary to diabetes mellitus have been recently analyzed with CCM using a multiparametric approach and termed corneal diabetic neuropathy (CDN) [21].
CDN, as defined using CCM, is characterized by relevant modifications (vs. control subjects) of CSNP parameters which may be summarized as follows: decrease in the number of fibers, branching pattern and number of beadings, and increase in nerve tortuosity in diabetic patients (Fig. 4) [21]. Rosenberg et al. [22] found a reduction in long nerve fiber bundle in patients with mild to moderate neuropathy, and a reduction in corneal mechanical sensitivity only in patients with severe neuropathy, suggesting that decrease in nerve fiber bundle counts precede impairment of corneal sensitivity and that reduction in neurotrophic stimuli in severe neuropathy may induce a thin epithelium that may lead to recurrent erosions. Chang et al. [24] defined diabetic alterations in the corneal innervations using CCM, finding a decrease in nerve fiber density and nerve branch density and an increase of tortuosity, demonstrating that reduced density in basal epithelial cell is correlated with changes in innervations. Malik et al. [26] showed a progressive reduction in the number of corneal nerve fibers in diabetes, suggesting enhanced degeneration, and showed reduction in the number of corneal nerve branches, suggesting a reduction in regenerative capacity, with a progression of neuropathic severity. Quattrini et al. [27] quantified nerve fiber pathological changes using CCM and found a progressive reduction in corneal nerve fiber and branch density, but the latter was significantly reduced even in diabetic patients without neuropathy. Kallinikos et al. [25] demonstrated that tortuosity coefficient of nerve fibers was significantly greater in the severe diabetic neuropathic group than in control subjects and in the mild and moderate neuropathic groups, suggesting that this morphologic abnormality relates to the severity of somatic neuropathy and may reflect an alteration in the degree of degeneration in
